Clinical Trials
13 trialsNCT07216443 2026-04-15
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Phase 2 Recruiting
NCT04904588 2026-03-18
ACCESS
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT06001385 2026-02-05
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Phase 2 Active not recruiting
NCT02158858 2025-10-08
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
Phase 1/2 Completed
NCT06501196 2025-09-24
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
BlossomHill Therapeutics
Phase 1 Recruiting
NCT03066648 2025-05-18
Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Novartis
Phase 1 Completed
NCT04741945 2024-11-22
Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT02452983 2022-06-02
SS1
Baylor College of Medicine
Phase 1 Terminated
NCT02809222 2021-04-19
PLASMYC
University Hospital, Tours
Phase NA Completed
NCT00637052 2021-02-08
A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia
Pfizer
Phase 1/2 Completed
NCT00943293 2014-03-17
Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies
University of Chicago
Phase 1 Terminated
NCT00943592 2014-02-27
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies
University of Chicago
Phase 1/2 Completed
NCT00502112 2011-10-12
A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)
Seagen Inc.
Phase 1 Completed